Level/ Typ | Code | Bezeichnung | Codesystem |
---|
1‑L | L04AA37 | Baricitinib | 1.2.276.0.76.5.498 |
0‑L | N02B | ANDERE ANALGETIKA UND ANTIPYRETIKA | 1.2.276.0.76.5.498 |
1‑L | N02BA | Salicylsäure und Derivate | 1.2.276.0.76.5.498 |
1‑L | N02BA01 | Acetylsalicylsäure | 1.2.276.0.76.5.498 |
1‑L | N02BA02 | Aloxiprin | 1.2.276.0.76.5.498 |
1‑L | N02BA03 | Cholinsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA04 | Natriumsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA05 | Salicylamid | 1.2.276.0.76.5.498 |
1‑L | N02BA06 | Salsalat | 1.2.276.0.76.5.498 |
1‑L | N02BA07 | Ethenzamid | 1.2.276.0.76.5.498 |
1‑L | N02BA08 | Morpholinsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA09 | Dipyrocetyl | 1.2.276.0.76.5.498 |
1‑L | N02BA10 | Benorilat | 1.2.276.0.76.5.498 |
1‑L | N02BA11 | Diflunisal | 1.2.276.0.76.5.498 |
1‑L | N02BA12 | Kaliumsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA13 | Lysin-Acetylsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA14 | Guacetisal | 1.2.276.0.76.5.498 |
1‑L | N02BA15 | Carbasalat calcium | 1.2.276.0.76.5.498 |
1‑L | N02BA16 | Imidazolsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA19 | Cholin-Magnesium-Tris-Salicylat | 1.2.276.0.76.5.498 |
1‑L | N02BA20 | Kombinationen | 1.2.276.0.76.5.498 |
1‑L | N02BA51 | Acetylsalicylsäure, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA55 | Salicylamid, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA57 | Ethenzamid, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA59 | Dipyrocetyl, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA65 | Carbasalat calcium, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA71 | Acetylsalicylsäure, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA75 | Salicylamid, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA77 | Ethenzamid, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BA79 | Dipyrocetyl, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB | Pyrazolone | 1.2.276.0.76.5.498 |
1‑L | N02BB01 | Phenazon | 1.2.276.0.76.5.498 |
1‑L | N02BB02 | Metamizol-Natrium | 1.2.276.0.76.5.498 |
1‑L | N02BB03 | Aminophenazon | 1.2.276.0.76.5.498 |
1‑L | N02BB04 | Propyphenazon | 1.2.276.0.76.5.498 |
1‑L | N02BB05 | Nifenazon | 1.2.276.0.76.5.498 |
1‑L | N02BB06 | Phenazonsalicylat | 1.2.276.0.76.5.498 |
1‑L | N02BB51 | Phenazon, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB52 | Metamizol-Natrium, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB53 | Aminophenazon, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB54 | Propyphenazon, Kombinationen exkl. Psycholeptika** | 1.2.276.0.76.5.498 |
1‑L | N02BB56 | Phenazonsalicylat, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB71 | Phenazon, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB72 | Metamizol-Natrium, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB73 | Aminophenazon, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB74 | Propyphenazon, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BB76 | Phenazonsalicylat, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BE | Anilide | 1.2.276.0.76.5.498 |
1‑L | N02BE01 | Paracetamol | 1.2.276.0.76.5.498 |
1‑L | N02BE03 | Phenacetin | 1.2.276.0.76.5.498 |
1‑L | N02BE04 | Bucetin | 1.2.276.0.76.5.498 |
1‑L | N02BE05 | Propacetamol | 1.2.276.0.76.5.498 |
1‑L | N02BE51 | Paracetamol, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BE53 | Phenacetin, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BE54 | Bucetin, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BE61 | Paracetamol, Kombinationen mit Coffein | 1.2.276.0.76.5.498 |
1‑L | N02BE71 | Paracetamol, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BE73 | Phenacetin, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BE74 | Bucetin, Kombinationen mit Psycholeptika | 1.2.276.0.76.5.498 |
1‑L | N02BG | Andere Analgetika und Antipyretika | 1.2.276.0.76.5.498 |
1‑L | N02BG02 | Rimazolium | 1.2.276.0.76.5.498 |
1‑L | N02BG03 | Glafenin | 1.2.276.0.76.5.498 |
1‑L | N02BG04 | Floctafenin | 1.2.276.0.76.5.498 |
1‑L | N02BG05 | Viminol | 1.2.276.0.76.5.498 |
1‑L | N02BG06 | Nefopam | 1.2.276.0.76.5.498 |
1‑L | N02BG07 | Flupirtin | 1.2.276.0.76.5.498 |
1‑L | N02BG08 | Ziconotid | 1.2.276.0.76.5.498 |
1‑L | N02BG09 | Methoxyfluran | 1.2.276.0.76.5.498 |
1‑L | N02BG10 | Cannabinoide | 1.2.276.0.76.5.498 |
1‑L | N02BG11 | Mirogabalin | 1.2.276.0.76.5.510 |
1‑L | N02BG12 | Tanezumab | 1.2.276.0.76.5.510 |
1‑L | N02BH | Homöopathische und anthroposophische Analgetika und Antipyretika | 1.2.276.0.76.5.498 |
1‑L | N02BH01 | Aconitum | 1.2.276.0.76.5.498 |
1‑L | N02BH10 | Verschiedene | 1.2.276.0.76.5.498 |
1‑L | N02BH20 | Kombinationen | 1.2.276.0.76.5.498 |
1‑L | N02BP | Pflanzliche Analgetika und Antipyretika | 1.2.276.0.76.5.498 |
1‑L | N02BP01 | Blauer Eisenhut | 1.2.276.0.76.5.498 |
1‑L | N02BP02 | Lindenblüten | 1.2.276.0.76.5.498 |
1‑L | N02BB54 | Propyphenazon, Kombinationen exkl. Psycholeptika | 1.2.276.0.76.5.498 |
0‑L | G01B | ANTIINFEKTIVA/ANTISEPTIKA IN KOMBINATION MIT CORTICOSTEROIDEN | 1.2.276.0.76.5.498 |
1‑L | G01BA | Antibiotika und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | G01BA01 | Antibiotika und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | G01BC | Chinolin-Derivate und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | G01BD | Antiseptika und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | G01BD01 | Antiseptika und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | G01BE | Sulfonamide und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | G01BE50 | Sulfonamide und Corticosteroide, Kombinationen mit Antibiotika | 1.2.276.0.76.5.498 |
1‑L | G01BF | Imidazol-Derivate und Corticosteroide | 1.2.276.0.76.5.498 |
0‑L | H02 | CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG | 1.2.276.0.76.5.498 |
1‑L | H02A | CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG, REIN | 1.2.276.0.76.5.498 |
1‑L | H02AA | Mineralocorticoide | 1.2.276.0.76.5.498 |
1‑L | H02AA01 | Aldosteron | 1.2.276.0.76.5.498 |
1‑L | H02AA02 | Fludrocortison | 1.2.276.0.76.5.498 |
1‑L | H02AA03 | Desoxycorton | 1.2.276.0.76.5.498 |
1‑L | H02AB | Glucocorticoide | 1.2.276.0.76.5.498 |
1‑L | H02AB01 | Betamethason | 1.2.276.0.76.5.498 |
1‑L | H02AB02 | Dexamethason | 1.2.276.0.76.5.498 |
1‑L | H02AB03 | Fluocortolon | 1.2.276.0.76.5.498 |
1‑L | H02AB04 | Methylprednisolon | 1.2.276.0.76.5.498 |
1‑L | H02AB05 | Paramethason | 1.2.276.0.76.5.498 |
1‑L | H02AB06 | Prednisolon | 1.2.276.0.76.5.498 |
1‑L | H02AB07 | Prednison | 1.2.276.0.76.5.498 |
1‑L | H02AB08 | Triamcinolon | 1.2.276.0.76.5.498 |
1‑L | H02AB09 | Hydrocortison | 1.2.276.0.76.5.498 |
1‑L | H02AB10 | Cortison | 1.2.276.0.76.5.498 |
1‑L | H02AB11 | Prednyliden | 1.2.276.0.76.5.498 |
1‑L | H02AB12 | Rimexolon | 1.2.276.0.76.5.498 |
1‑L | H02AB13 | Deflazacort | 1.2.276.0.76.5.498 |
1‑L | H02AB14 | Cloprednol | 1.2.276.0.76.5.498 |
1‑L | H02AB15 | Meprednison | 1.2.276.0.76.5.498 |
1‑L | H02AB17 | Cortivazol | 1.2.276.0.76.5.498 |
1‑L | H02AB51 | Betamethason-Depot | 1.2.276.0.76.5.498 |
1‑L | H02AB54 | Methylprednisolon-Depot | 1.2.276.0.76.5.498 |
1‑L | H02AB56 | Prednisolon-Depot | 1.2.276.0.76.5.498 |
1‑L | H02AB58 | Triamcinolon-Depot | 1.2.276.0.76.5.498 |
1‑L | H02B | CORTICOSTEROIDE ZUR SYSTEMISCHEN ANWENDUNG, KOMBINATIONEN | 1.2.276.0.76.5.498 |
1‑L | H02BX | Corticosteroide zur systemischen Anwendung, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX01 | Methylprednisolon, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX02 | Dexamethason, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX06 | Prednisolon, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX08 | Triamcinolon, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX09 | Betamethason, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX20 | Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02BX21 | Desoxycorton, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | H02C | NEBENNIERENHEMMSTOFFE | 1.2.276.0.76.5.498 |
1‑L | H02CA | Anticorticosteroide | 1.2.276.0.76.5.498 |
1‑L | H02CA01 | Trilostan | 1.2.276.0.76.5.498 |
1‑L | H02CA02 | Ketoconazol | 1.2.276.0.76.5.498 |
0‑L | M01BA | Antiphlogistika/Antirheumatika in Kombination mit Corticosteroiden | 1.2.276.0.76.5.498 |
1‑L | M01BA01 | Phenylbutazon und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA02 | Dipyrocetyl und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA03 | Acetylsalicylsäure und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA04 | Mofebutazon und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA05 | Oxyphenbutazon und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA06 | Salicylamid und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA07 | Metamizol und Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | M01BA08 | Kebuzon und Corticosteroide | 1.2.276.0.76.5.498 |
0‑L | R03AK | Sympathomimetika in Kombination mit Corticosteroiden oder anderen Mitteln, exkl. Anticholinergika | 1.2.276.0.76.5.498 |
1‑L | R03AK01 | Epinephrin und andere Mittel bei obstruktiven Atemwegserkrankungen | 1.2.276.0.76.5.498 |
1‑L | R03AK02 | Isoprenalin und andere Mittel bei obstruktiven Atemwegserkrankungen | 1.2.276.0.76.5.498 |
1‑L | R03AK03 | Fenoterol und Cromoglicinsäure, Dinatriumsalz | 1.2.276.0.76.5.498 |
1‑L | R03AK04 | Salbutamol und Cromoglicinsäure, Dinatriumsalz | 1.2.276.0.76.5.498 |
1‑L | R03AK05 | Reproterol und Cromoglicinsäure, Dinatriumsalz | 1.2.276.0.76.5.498 |
1‑L | R03AK06 | Salmeterol und Fluticason | 1.2.276.0.76.5.498 |
1‑L | R03AK07 | Formoterol und Budesonid | 1.2.276.0.76.5.498 |
1‑L | R03AK08 | Formoterol und Beclometason | 1.2.276.0.76.5.498 |
1‑L | R03AK09 | Formoterol und Mometason | 1.2.276.0.76.5.498 |
1‑L | R03AK10 | Vilanterol und Fluticasonfuroat | 1.2.276.0.76.5.498 |
1‑L | R03AK11 | Formoterol und Fluticason | 1.2.276.0.76.5.498 |
1‑L | R03AK12 | Salmeterol und Budesonid | 1.2.276.0.76.5.498 |
1‑L | R03AK13 | Salbutamol und Beclometason | 1.2.276.0.76.5.498 |
0‑L | R03AL | Sympathomimetika in Kombination mit Anticholinergika inkl. Dreifachkombinationen mit Corticosteroiden | 1.2.276.0.76.5.498 |
1‑L | R03AL01 | Fenoterol und Ipratropiumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL02 | Salbutamol und Ipratropiumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL03 | Vilanterol und Umeclidiniumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL04 | Indacaterol und Glycopyrroniumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL05 | Formoterol und Aclidiniumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL06 | Olodaterol und Tiotropiumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL07 | Formoterol und Glycopyrroniumbromid | 1.2.276.0.76.5.498 |
1‑L | R03AL08 | Vilanterol, Umeclidiniumbromid und Fluticasonfuroat | 1.2.276.0.76.5.498 |
1‑L | R03AL09 | Formoterol, Glycopyrroniumbromid und Beclometason | 1.2.276.0.76.5.498 |
0‑L | S02B | CORTICOSTEROIDE | 1.2.276.0.76.5.498 |
1‑L | S02BA | Corticosteroide | 1.2.276.0.76.5.498 |
1‑L | S02BA01 | Hydrocortison | 1.2.276.0.76.5.498 |
1‑L | S02BA03 | Prednisolon | 1.2.276.0.76.5.498 |
1‑L | S02BA06 | Dexamethason | 1.2.276.0.76.5.498 |
1‑L | S02BA07 | Betamethason | 1.2.276.0.76.5.498 |
1‑L | S02BA08 | Fluocinolonacetonid | 1.2.276.0.76.5.498 |
1‑L | S02BA56 | Dexamethason, Kombinationen | 1.2.276.0.76.5.498 |
0‑L | L04AD | Calcineurin-Inhibitoren | 1.2.276.0.76.5.498 |
1‑L | L04AD01 | Ciclosporin | 1.2.276.0.76.5.498 |
1‑L | L04AD02 | Tacrolimus | 1.2.276.0.76.5.498 |
1‑L | L04AD03 | Voclosporin | 1.2.276.0.76.5.498 |
0‑L | L04AB | Tumornekrosefaktor alpha(TNF-alpha)-Inhibitoren | 1.2.276.0.76.5.498 |
1‑L | L04AB01 | Etanercept | 1.2.276.0.76.5.498 |
1‑L | L04AB02 | Infliximab | 1.2.276.0.76.5.498 |
1‑L | L04AB03 | Afelimomab | 1.2.276.0.76.5.498 |
1‑L | L04AB04 | Adalimumab | 1.2.276.0.76.5.498 |
1‑L | L04AB05 | Certolizumab pegol | 1.2.276.0.76.5.498 |
1‑L | L04AB06 | Golimumab | 1.2.276.0.76.5.498 |
1‑L | L04AB07 | Opinercept | 1.2.276.0.76.5.498 |
0‑L | L04AC | Interleukin-Inhibitoren | 1.2.276.0.76.5.498 |
1‑L | L04AC01 | Daclizumab | 1.2.276.0.76.5.498 |
1‑L | L04AC02 | Basiliximab | 1.2.276.0.76.5.498 |
1‑L | L04AC03 | Anakinra | 1.2.276.0.76.5.498 |
1‑L | L04AC04 | Rilonacept | 1.2.276.0.76.5.498 |
1‑L | L04AC05 | Ustekinumab | 1.2.276.0.76.5.498 |
1‑L | L04AC07 | Tocilizumab | 1.2.276.0.76.5.498 |
1‑L | L04AC08 | Canakinumab | 1.2.276.0.76.5.498 |
1‑L | L04AC09 | Briakinumab | 1.2.276.0.76.5.498 |
1‑L | L04AC10 | Secukinumab | 1.2.276.0.76.5.498 |
1‑L | L04AC11 | Siltuximab | 1.2.276.0.76.5.498 |
1‑L | L04AC12 | Brodalumab | 1.2.276.0.76.5.498 |
1‑L | L04AC13 | Ixekizumab | 1.2.276.0.76.5.498 |
1‑L | L04AC14 | Sarilumab | 1.2.276.0.76.5.498 |
1‑L | L04AC15 | Sirukumab | 1.2.276.0.76.5.498 |
1‑L | L04AC16 | Guselkumab | 1.2.276.0.76.5.498 |
1‑L | L04AC17 | Tildrakizumab | 1.2.276.0.76.5.498 |
1‑L | L04AC18 | Risankizumab | 1.2.276.0.76.5.498 |
0‑L | L03AB | Interferone | 1.2.276.0.76.5.498 |
1‑L | L03AB01 | Interferon alfa, natürlich | 1.2.276.0.76.5.498 |
1‑L | L03AB02 | Interferon beta, natürlich | 1.2.276.0.76.5.498 |
1‑L | L03AB03 | Interferon gamma | 1.2.276.0.76.5.498 |
1‑L | L03AB04 | Interferon alfa-2a | 1.2.276.0.76.5.498 |
1‑L | L03AB05 | Interferon alfa-2b | 1.2.276.0.76.5.498 |
1‑L | L03AB06 | Interferon alfa-n1 | 1.2.276.0.76.5.498 |
1‑L | L03AB07 | Interferon beta-1a | 1.2.276.0.76.5.498 |
1‑L | L03AB08 | Interferon beta-1b | 1.2.276.0.76.5.498 |
1‑L | L03AB09 | Interferon alfacon-1 | 1.2.276.0.76.5.498 |
1‑L | L03AB10 | Peginterferon alfa-2b | 1.2.276.0.76.5.498 |
1‑L | L03AB11 | Peginterferon alfa-2a | 1.2.276.0.76.5.498 |
1‑L | L03AB12 | Albinterferon alfa-2b | 1.2.276.0.76.5.498 |
1‑L | L03AB13 | Peginterferon beta-1a | 1.2.276.0.76.5.498 |
1‑L | L03AB14 | Cepeginterferon alfa-2b | 1.2.276.0.76.5.498 |
1‑L | L03AB15 | Ropeginterferon alfa-2b | 1.2.276.0.76.5.498 |
1‑L | L03AB18 | Interferon gamma-1b | 1.2.276.0.76.5.498 |
1‑L | L03AB60 | Peginterferon alfa-2b, Kombinationen | 1.2.276.0.76.5.498 |
1‑L | L03AB61 | Peginterferon alfa-2a, Kombinationen | 1.2.276.0.76.5.498 |
0‑L | A12CB | Zink | 1.2.276.0.76.5.498 |
1‑L | A12CB01 | Zinksulfat | 1.2.276.0.76.5.498 |
1‑L | A12CB02 | Zinkgluconat | 1.2.276.0.76.5.498 |
1‑L | A12CB03 | Zinkprotein-Komplex | 1.2.276.0.76.5.498 |
1‑L | A12CB05 | Zinkhydrogenaspartat | 1.2.276.0.76.5.498 |
1‑L | A12CB06 | Zinkorotat | 1.2.276.0.76.5.498 |
0‑L | D01AC20 | Imidazole/Triazole in Kombination mit Corticosteroiden | 1.2.276.0.76.5.498 |
0‑L | J05AE08 | Atazanavir | 1.2.276.0.76.5.498 |
0‑L | J05AR15 | Atazanavir und Cobicistat | 1.2.276.0.76.5.498 |
0‑L | J05AR23 | Atazanavir und Ritonavir | 1.2.276.0.76.5.498 |
0‑L | J05AE10 | Darunavir | 1.2.276.0.76.5.498 |
0‑L | J05AR14 | Darunavir und Cobicistat | 1.2.276.0.76.5.498 |
0‑L | J05AR22 | Emtricitabin, Tenofoviralafenamid, Darunavir und Cobicistat | 1.2.276.0.76.5.498 |
0‑L | P01BA01 | Chloroquin | 1.2.276.0.76.5.498 |
0‑L | P01BA02 | Hydroxychloroquin | 1.2.276.0.76.5.498 |
0‑L | P02CF01 | Ivermectin | 1.2.276.0.76.5.498 |
0‑L | D11AX22 | Ivermectin | 1.2.276.0.76.5.498 |
0‑L | P02CF01 | Ivermectin | 1.2.276.0.76.5.498 |
0‑L | J05AR10 | Lopinavir und Ritonavir | 1.2.276.0.76.5.498 |
0‑L | J05AB06 | Ganciclovir | 1.2.276.0.76.5.498 |
0‑L | S01AD09 | Ganciclovir | 1.2.276.0.76.5.498 |
0‑L | J05AH02 | Oseltamivir | 1.2.276.0.76.5.498 |
0‑L | J05AP01 | Ribavirin | 1.2.276.0.76.5.498 |
0‑L | B02AB04 | Camostat | 1.2.276.0.76.5.498 |
0‑L | J05AX27 | Favipiravir | 1.2.276.0.76.5.498 |
0‑L | L04AC07 | Tocilizumab | 1.2.276.0.76.5.498 |
0‑L | L04AC14 | Sarilumab | 1.2.276.0.76.5.498 |
0‑L | S01XA18 | Ciclosporin | 1.2.276.0.76.5.498 |
0‑L | D11AH01 | Tacrolimus | 1.2.276.0.76.5.498 |
0‑L | L04AA10 | Sirolimus | 1.2.276.0.76.5.498 |
0‑L | L04AA18 | Everolimus | 1.2.276.0.76.5.498 |
0‑L | L01XE10 | Everolimus | 1.2.276.0.76.5.498 |
0‑L | L04AA18 | Everolimus | 1.2.276.0.76.5.498 |
0‑L | L01XE18 | Ruxolitinib | 1.2.276.0.76.5.498 |
0‑L | M04AC01 | Colchicin | 1.2.276.0.76.5.498 |
0‑L | S01AD05 | Interferon | 1.2.276.0.76.5.498 |
0‑L | A11CC06 | Calcifediol | 1.2.276.0.76.5.498 |
|